HMGA2 as a prognostic and immune biomarker in hepatocellular carcinoma: Comprehensive analysis of the HMG family and experiments validation
PLOS ONE · 26.11.2024 · 19 (11) · e0311204
DOI: 10.1371/journal.pone.0311204 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 26.11.2024. Verfasst von Qiangqiang Zhong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, HMGA2 Protein, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program of China.
Abstract (Originalsprache)
The molecular mechanisms underlying hepatocellular carcinoma (HCC) are complex and not fully understood. This study aims to explore the expression and clinical significance of High Mobility Group (HMG) proteins in HCC to identify potential prognostic biomarkers and therapeutic targets. Bioinformatic analyses were performed using data from The Cancer Genome Atlas (TCGA) and other databases. Expression levels of HMGs were validated in HCC cell lines using qRT-PCR, and functional studies were conducted by knocking down HMGA2.HMG family members, particularly HMGA1, HMGA2, HMGB2, and HMGN1, were significantly upregulated in HCC tissues compared to normal tissues. High expression levels of these proteins were associated with poor overall survival and disease-specific survival in HCC patients. Knockdown of HMGA2 in HCC cell lines led to reduced cell proliferation, migration, and invasion. HMGA2, along with other HMG family members, emerges as a potential prognostic biomarker and therapeutic target in HCC. This study provides new insights into the role of HMG proteins in HCC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.
- Laboratory of Metabolic Abnormalities and Vascular Aging Huazhong University of Science and Technology, Wuhan, PR China.
- Department of Geriatrics, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.
- Department of Gastroenterology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, PR China.
- Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.
ORCID-Profile: Baokang Zhao, Xiangjie Liu
Förderung
- the National Key Research and Development Program of China
Zitieren
APA
Zhong, Q., Zhao, B., She, X., & Liu, X. (2024). HMGA2 as a prognostic and immune biomarker in hepatocellular carcinoma: Comprehensive analysis of the HMG family and experiments validation. PLOS ONE, 19(11), e0311204. https://doi.org/10.1371/journal.pone.0311204
Vancouver
Zhong Q, Zhao B, She X, Liu X. HMGA2 as a prognostic and immune biomarker in hepatocellular carcinoma: Comprehensive analysis of the HMG family and experiments validation. PLOS ONE. 2024;19(11):e0311204. doi:10.1371/journal.pone.0311204
BibTeX
@article{Zhong2024,
author = {Zhong, Qiangqiang and Zhao, Baokang and She, Xiao and Liu, Xiangjie},
title = {HMGA2 as a prognostic and immune biomarker in hepatocellular carcinoma: Comprehensive analysis of the HMG family and experiments validation},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {11},
pages = {e0311204},
doi = {10.1371/journal.pone.0311204}
}
EUVIMED